Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - United States

United States

The Other Vaccines market in the United States is anticipated to achieve a revenue of €22.94bn by the year 2024.
It is expected to exhibit a compound annual growth rate (CAGR) of 10.21% from 2024 to 2029, ultimately leading to a market volume of €37.30bn by 2029.
When compared globally, United States is projected to generate the highest revenue, with €22.94bn in 2024.
The United States is witnessing a surge in demand for other vaccines due to increased public awareness and proactive government initiatives.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Other Vaccines market in United States has been experiencing significant growth in recent years.

Customer preferences: One of the main reasons for the growth of the Other Vaccines market in the United States is the increasing awareness among the population about the importance of vaccination. With the rise in the number of diseases that can be prevented by vaccines, people are becoming more conscious about protecting themselves and their families from these illnesses.

Trends in the market: Another trend that has been driving the growth of the Other Vaccines market in the United States is the increasing demand for travel vaccines. As more and more people travel internationally, they are exposed to diseases that are not prevalent in the United States. To protect themselves from these diseases, travelers are seeking out vaccines that are specifically designed for the regions they are visiting.

Local special circumstances: The United States is also home to a large number of pharmaceutical companies that are involved in the development and manufacture of vaccines. This has led to a highly competitive market, with companies constantly striving to develop new and innovative vaccines that can provide better protection against diseases.

Underlying macroeconomic factors: The growth of the Other Vaccines market in the United States can also be attributed to the country's strong healthcare system. With a high level of investment in healthcare and a large number of healthcare professionals, the United States is well-equipped to handle the demand for vaccines.In conclusion, the Other Vaccines market in the United States is growing rapidly due to a combination of factors, including increasing awareness about the importance of vaccination, rising demand for travel vaccines, a highly competitive market, and a strong healthcare system. As the population continues to grow and travel becomes more common, the demand for vaccines is likely to continue to rise, making the Other Vaccines market an attractive area for investment and innovation.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.